ArticleScientific reports2019
Hemophilia A and B mice, but not VWF
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Bone and Hemophilia: The Role of Factor VIII-Systematic Review.International journal of molecular sciences · 2025Pooled it
- Factor VIII restores bone parameters and modulates muscle proteo-metabolome in Factor VIII knockout male mice.Bone research · 2026Article
- Emerging Therapies in Hemophilia: Improving Equitable Access to Care.Journal of blood medicine · 2025Review
- Murine vs. Human Osteoblast Responses to Coagulation and Inflammatory Factors: Reconsidering the Use of Animal Models in Hemophilia a Research.Biomedicines · 2024Article
- Effects of coagulation factors on bone cells and consequences of their absence in haemophilia a patients.Scientific reports · 2024Article
- Haemophilia and Fragility Fractures: From Pathogenesis to Multidisciplinary Approach.International journal of molecular sciences · 2023Review
- Pathogenesis and treatment of osteoporosis in patients with hemophilia.Archives of osteoporosis · 2023Review
- Drug discovery in spinal cord injury-induced osteoporosis: a text mining-based study.Annals of translational medicine · 2022Article
- Factor VIII as a potential player in cancer pathophysiology.Journal of thrombosis and haemostasis : JTH · 2022Article
- Low Bone Mineral Density in Hemophiliacs.Frontiers in medicine · 2022Review
- Deletion of Coagulation Factor IX Compromises Bone Mass and Strength: Murine Model of Hemophilia B (Christmas Disease).Calcified tissue international · 2021Article
- Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While joint damage is the primary co-morbidity of hemophilia, osteoporosis and osteopenia are also observed. Coagulation factor VIII deficient (FVIII
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.